Stock of the Day - December 27, 2021

Halozyme Therapeutics (HALO)

$121.84

+$0.33 (+0.3%)

Market Cap: $13.83B

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Trend

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has benefited from a series of bullish analyst calls, strong earnings expectations and continued optimism about its partnered-drug delivery platform. The shares are trading near their 52-week high, with momentum supported by a 50-day moving average well above the 200-day average.

Zacks upgraded HALO from “hold” to “strong buy,” citing strong price performance and favorable earnings trends. The upgrade helped reinforce investor momentum. 5 Stocks to Buy Using the Relative Price Strength Strategy
H.C. Wainwright reaffirmed its Buy rating on Halozyme, signaling continued confidence in the company’s growth outlook and commercial execution. H.C. Wainwright Reaffirms Their Buy Rating on Halozyme
TD Cowen projected substantial price appreciation for HALO, adding to the positive analyst sentiment surrounding the stock. TD Cowen Forecasts Strong Price Appreciation for Halozyme
Halozyme was highlighted in multiple stock-selection reports as a relative-strength and top-ranked nontechnology Nasdaq pick, based on strong price performance and rising earnings estimates. Buy 5 Top-Ranked Non-Tech Nasdaq Stocks
An expanded agreement with argenx could improve Halozyme’s long-term royalty and licensing opportunity, but investors are weighing the deal’s ultimate financial contribution and execution risks. Is Expanded Argenx Deal Altering the Investment Case for Halozyme?

The broader backdrop is also supportive: Halozyme recently exceeded quarterly earnings and revenue expectations and raised full-year guidance. However, its elevated valuation means the stock may remain sensitive to partnership execution and whether future growth justifies the already strong share-price gains.

← Previous Stock of the Day Next Stock of the Day →

Halozyme Therapeutics (HALO)

About Halozyme Therapeutics

Today's Trend

Recent News